Enoblituzumab
Enoblituzumab (pronunciation: e-nob-li-tuz-u-mab) is a type of monoclonal antibody used in cancer treatment. It is currently under investigation for its potential use in the treatment of various types of cancer, including head and neck cancer, lung cancer, and melanoma.
Etymology
The name "Enoblituzumab" is derived from the International Nonproprietary Names (INN), where "Eno" refers to the target (B7-H3), "li" signifies immunoglobulin, "tuz" indicates humanized, and "mab" stands for monoclonal antibody.
Mechanism of Action
Enoblituzumab works by binding to the B7-H3 protein, which is often overexpressed in cancer cells. This binding triggers an immune response that targets and destroys the cancer cells. This mechanism of action is similar to other immunotherapy drugs, which work by boosting the body's immune system to fight cancer.
Related Terms
- Monoclonal Antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Immunotherapy: A type of therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer, infection, and other diseases.
- B7-H3: A protein that is often overexpressed in cancer cells and can be targeted by certain drugs to treat cancer.
Clinical Trials
Enoblituzumab is currently in clinical trials for its potential use in treating various types of cancer. These trials are investigating the drug's safety, efficacy, and optimal dosing.
See Also
External links
- Medical encyclopedia article on Enoblituzumab
- Wikipedia's article - Enoblituzumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski